Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...
Revenue: $2.5 million for the quarter ended December 31, 2024.
Total Operating Expenses: $163.9 million for the quarter ended December 31, 2024.
Cash and Investments: $552.9 million at December 31, 2024; pro forma cash and investments would be $1.4 billion including Sarepta payments.
Cash Used by Operating Activities: $146.3 million for the quarter ended December 31, 2024.
Common Shares Outstanding: 125.6 million at December 31, 2024.
Warning! GuruFocus has detected 5 Warning Signs with ARWR.
Release Date: February 10, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) closed a significant license and collaboration agreement with Sarepta Therapeutics, expected to bring in $1.375 billion in cash payments.
The company is now funded into 2028, with potential for multiple commercial launches by Arrowhead and its partners.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) anticipates its first commercial launch of plozasiran, which could drive substantial growth pending FDA approval.
The company is focusing on three primary value drivers: plozasiran, obesity, and CNS, which are expected to fuel growth in the near term.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has a robust potential catalyst calendar for 2025, with multiple key events expected throughout the year.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported a net loss of $173.1 million for the quarter ended December 31, 2024, compared to a net loss of $132.9 million in the previous year.
Revenue for the quarter was $2.5 million, down from $3.6 million in the same quarter of the previous year.
The company experienced increased operating expenses, primarily due to higher candidate costs and salaries as its pipeline of clinical candidates advanced.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) needs additional capital to start a cardiovascular outcomes trial (CVOT) for plozasiran, despite having a significant cash balance.
The company faces challenges in expanding the market for its products, as the industry requires education and awareness to address largely untreated diseases.
Q: Can you discuss the potential of ARO-INHBE in obesity treatment and its role as a standalone or combination therapy? A: James Hamilton, Chief of Discovery and Translational Medicine, explained that ARO-INHBE is being studied both as a monotherapy and in combination with tirzepatide. The development path will depend on the data outcomes, and there is no specific target to hit at this stage. The obesity market is diverse, and Arrowhead is developing a suite of drug candidates to address various needs.
Q: What feedback have you received from doctors regarding APOC3 and current commercial launches? A: Christopher Anzalone, President and CEO, noted that feedback on plozasiran has been positive, with physicians and patient societies expressing enthusiasm due to its differentiating attributes, despite other available options.
Q: Will the Phase I/IIa trial for ARO-INHBE and ARO-ALK7 provide weight loss or body composition data? A: James Hamilton confirmed that the trial will assess body composition using full-body MRI and weight loss, alongside safety, plasma PK, and biomarker activity in the blood.
Q: Can you provide more details on the SHASTA-5 study and its potential impact on pancreatitis outcomes? A: The SHASTA-5 study is the first of its kind focusing on pancreatitis as the primary endpoint. Enrollment timelines are uncertain, and the study will continue until the required number of events are observed. It is expected to be significant for payers and health technology assessment organizations, particularly outside the US.
Q: What are Arrowhead's plans for plozasiran's commercialization in Europe? A: Andy Davis, Senior Vice President, Cardiovascular/Metabolic Franchise Head, stated that Arrowhead plans to commercialize plozasiran in European markets with a commercial partner, with more details to be provided in the future.
Q: How does Arrowhead view plozasiran's competitive positioning relative to olozarsen in FCS and severe hypertriglyceridemia? A: Andy Davis highlighted plozasiran's unprecedented triglyceride reduction, ability to achieve guideline-directed risk thresholds, and statistically significant reduction in acute pancreatitis risk as key differentiators. Bruce Given added that the market is more about expansion and education rather than direct competition.
Q: What is the strategy for the CVOT study for plozasiran, and what are the gating factors for its initiation? A: Christopher Anzalone stated that the CVOT study is contingent on securing additional capital. The study is scientifically important to assess residual cardiovascular risk related to triglycerides, and Arrowhead is exploring partnerships to fund it.
Q: What are the plans for zodasiran in HoFH, and how does it compare to existing treatments? A: Bruce Given explained that zodasiran targets the same patient population as existing treatments but offers quarterly dosing and potentially fewer allergic reactions. The focus is on patients with high LDL cholesterol despite high-dose statins and PCSK9 inhibitors.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 minutes ago
- Associated Press
LINE LOSS ALERT: Lineage, Inc. Investors with Losses are Reminded of the September 30 Class Action Deadline – Contact BFA Law (NASDAQ:LINE)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Lineage, Inc. (NASDAQ: LINE) and certain of the Company's senior executives and directors for potential violations of the federal securities laws. If you invested in Lineage, you are encouraged to obtain additional information by visiting: Investors have until September 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to Lineage's registration statement for its initial public offering held on or about July 25, 2024. The case is pending in the U.S. District Court for the Eastern District of Michigan and is captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., et al., No. 2:25-cv-12383. Why Was Lineage Sued Under the Federal Securities Laws? Lineage is a cold storage focused real estate investment trust ('REIT'). Through its Global Warehousing Segment, Lineage owns and operates hundreds of temperature-controlled storage facilities used by companies to store food and other perishable products. As alleged, Lineage's IPO documents touted its 'consistent cold chain demand,' which purportedly provided Lineage 'with strong cash flows even during periods of broader economic stress.' The IPO documents also represented that the lingering effects of the COVID-19 pandemic had 'accelerated trends that . . . have the potential to be growth engines for the industry in coming years.' In truth, Lineage was allegedly in the midst of a sustained downturn, as its customers destocked excess inventory built up during the COVID-19 pandemic, and also shifted to leaner inventories on a go-forward basis and as more cold-storage supply came on line. Events Following the IPO On February 26, 2025, Lineage announced its fiscal Q4 2024 financial results, revealing that customers had been 'unwinding' previously 'overbuil[t]' levels of inventory, returning to a 'more normal seasonal pattern' that was expected to 'continue moving forward.' Lineage conducted its IPO at $78 per share. Since the IPO, the price of Lineage stock has fallen dramatically, to lows near $40 per share—approximately half the IPO price. Click here for more information: What Can You Do? If you invested in Lineage you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Associated Press
10 minutes ago
- Associated Press
RXST LOSS ALERT: RxSight, Inc. Investors with Losses are Reminded of the September 22 Class Action Deadline – Contact BFA Law (NASDAQ:RXST)
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. RxSight, Inc., et al., No. 25-cv- 01596. Why Was RxSight Sued for Securities Fraud? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales and failed to disclose 'adoption challenges' in its products. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth Is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024' and '[a]doption challenges over the last few quarters.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Yahoo
13 minutes ago
- Yahoo
After Gaining $394 Billion in Market Cap in 3 Days, Is Apple Stock on Its Way to Joining Nvidia and Microsoft in the $4 Trillion Club?
Key Points Apple's U.S. manufacturing investment could lower its tariff expense. The company's results are improving, but growth is still sluggish. Apple needs to justify its lofty valuation with AI-related product upgrades that are well-received by its diverse user base. 10 stocks we like better than Apple › After closing at $202.69 per share on Aug. 5, Apple (NASDAQ: AAPL) stock soared a staggering 13% in just three days to finish Aug. 8 at $229.09 per share. The move pole-vaulted the tech giant's market cap to $3.404 trillion -- a whopping $394 billion gain. That's like creating a company the size of Home Depot out of thin air. After languishing for most of the year, let's determine if Apple has what it takes to join Nvidia (NASDAQ: NVDA) and Microsoft (NASDAQ: MSFT) in the $4 trillion market cap club, and if the growth stock is a buy now. Apple's massive news Apple's sudden pop came in response to its $100 billion manufacturing program. Announced last week, the program will create American jobs and onshore some of Apple's complex supply chain. Due to Apple CEO Tim Cook's visit to the White House and Apple's manufacturing commitment, President Trump said that Apple would be 100% exempt from a specific tariff on imported semiconductors. The potential for Apple to reduce its costly tariff expense, and maybe even get government support for its onshoring efforts, is undoubtedly a boon for the company's near-term prospects. Apple isn't the only mega-cap company that is trying to work with the current administration on tariffs. On Monday, reports indicated that Nvidia made a deal with President Trump, allowing the chipmaker to resume exporting its H20 chips in exchange for giving the U.S. government 15% of its revenue from China. The H20 is a scaled-down version of Nvidia's most advanced chips, which are custom-built for Chinese markets to comply with trade restrictions. The current administration intends to retain certain tariffs, but it also appears willing to negotiate deals with big businesses. Apple's manufacturing news is positive, based on the near-term impact of tariffs. The investment could help Apple reduce its sensitivity to trade tensions and geopolitical risk. However, it's unclear how it impacts Apple's long-term investment thesis. Apple has mastered the art of managing a global supply chain to achieve cost advantages and boost its profit margins. Onshoring some of its supply chain could lead to higher costs. However, Apple has yet to make a meaningful splash in artificial intelligence (AI) -- which is one of the main reasons why the tech giant has been lagging behind the performance of other, more defined AI winners like Nvidia and Microsoft. In Apple's defense, the company has built on Apple Intelligence and released a new design update called Liquid Glass. Overall, the market is not impressed with the company's AI efforts, considering how sluggish Apple's growth has been in recent years. Apple's earnings growth doesn't justify its lofty valuation Apple has heavily relied on its high-margin services segment and stock buybacks to drive earnings to offset weak results from its product segment. Apple's services, which include iCloud, Apple Music, and Apple TV+, have been the standout for years now. But Apple's bottom line depends more on key products, like iPhone, Mac, iPad, and wearables. Investors breathed a sigh of relief after Apple's latest quarter -- the third quarter of fiscal 2025 -- which showed a significant improvement in its product segment. Revenue grew 10% and diluted earnings per share (EPS) jumped 12% including double-digit growth in iPhone, Mac, and services. Despite the solid quarter, Apple's net income has slightly declined over the last three years, so its earnings are only up due to buybacks. But the stock price has gone up substantially, which has made Apple relatively expensive. Apple's results are headed in the right direction, but the valuation is far from cheap. In fact, Apple's forward price-to-earnings (P/E) ratio, which is the stock price divided by analyst consensus EPS estimates over the next 12 months, is higher than its five-year and 10-year median P/E ratios. Even if Apple performs as expected and the stock price doesn't move for a year, it will still be relatively expensive. Apple has to earn $4 trillion the hard way Apple is taking the right approach to integrating AI across its product suite. Apple's competitive advantages are its design, user-friendly products, seamless integration of software and hardware, and comprehensive product offerings for consumers and businesses. In other words, the everyday usefulness of Apple's AI features is the most important performance indicator. Investors who agree with Apple's deliberate approach to AI may still want to consider buying the stock now, despite the premium valuation. However, given how pricey Apple is, its road to $4 trillion in market cap will likely need to come from earnings growth rather than valuation expansion. With a market cap of $3.418 trillion at the time of this writing, Apple would have to jump 17% to cross $4 trillion. It could certainly grow earnings by that much in a year or two. And if investors like what the company is doing with AI, it could maintain its higher-than-historical valuation. All told, I expect Apple to cross $4 trillion in market cap by the end of 2026 -- but investors shouldn't expect the company to get there overnight -- even after adding $392 billion in market cap in just three days. Should you invest $1,000 in Apple right now? Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Apple, Home Depot, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. After Gaining $394 Billion in Market Cap in 3 Days, Is Apple Stock on Its Way to Joining Nvidia and Microsoft in the $4 Trillion Club? was originally published by The Motley Fool Sign in to access your portfolio
